Understanding PSA Levels in Transgender and Non-Binary Individuals: A Groundbreaking Study

This important observational study led by Queen Mary University of London seeks to establish proper prostate-specific antigen (PSA) reference ranges specifically for transgender and non-binary people with prostates (TNBPP) who are undergoing gender-affirming hormone therapy (GAHT) or have had bilateral orchidectomy. Currently, medical professionals rely on PSA reference ranges established for cisgender men, which may not be appropriate for this population.

Why This Research Matters:

• PSA testing is crucial for prostate cancer screening, but current standards may not apply to transgender women and non-binary individuals on hormone therapy
• Gender-affirming treatments significantly alter hormone levels that affect prostate tissue
• Without proper reference ranges, doctors might misinterpret PSA results leading to unnecessary biopsies or missed diagnoses

Study Details:

The research will enroll an estimated 500 participants divided into age groups (40-49, 50-59, 60-79, and 70+ years old). Participants must be over 40, identify as transgender or non-binary, have a prostate, and either be on hormone therapy for at least 3 months or have had bilateral orchidectomy.

What Makes This Study Unique:

• First large-scale effort to establish PSA norms for this population
• Results could transform prostate cancer screening protocols for transgender care
• Includes diverse age groups to account for natural PSA variations

Potential Impact:

This research could lead to more accurate prostate cancer screening for transgender women and non-binary individuals with prostates. Proper reference ranges would help clinicians distinguish between normal PSA levels and those suggesting possible prostate cancer. The study also tracks prostate cancer diagnoses during the research period, providing valuable data on incidence rates in this population.

Why Inclusive Medical Research Matters:

Historically, medical research has focused primarily on cisgender populations, leaving gaps in our understanding of transgender health. Studies like this are vital for developing evidence-based care standards. As more people access gender-affirming treatments, we need better data to guide their healthcare beyond transition-related care. This study represents an important step toward equitable medical standards that serve all patients effectively, regardless of gender identity.

The importance of this research extends beyond prostate health - it highlights the broader need for gender-inclusive medical research. Many diagnostic tests and treatment protocols were developed without considering transgender and non-binary patients, potentially compromising care quality. By establishing population-specific reference ranges, we move closer to truly personalized medicine that respects and responds to all patients' unique biological and social circumstances.